Canagliflozin extends lifespan in genetically heterogeneous male but not female mice.

Richard A Miller
David E Harrison, The Jackson Laboratory
David B Allison
Molly A. Bogue, The Jackson Laboratory
Lucas K Debarba
Vivian Diaz
Elizabeth Fernandez
Andrzej T Galecki
W Timothy Garvey
Hashan Jayarathne
Navasuja Kumar
Martin Javors
Warren Ladiges
Francesca Macchiarini
James F Nelson
Peter C. Reifsnyder, The Jackson Laboratory
Nadia Rosenthal, The Jackson Laboratory
Marianna Sadagurski
Adam B Salmon
Daniel L Smith
Jessica M Snyder
David B Lombard
Randy Strong


Canagliflozin (Cana) is an inhibitor of the sodium glucose transporter 2 (SGLT2), and is thought to act by blocking renal reuptake and intestinal absorption of glucose. Cana is FDA-approved for treatment of diabetes, and affords protection from cardiovascular and kidney diseases. In the context of the mouse Interventions Testing Program, genetically heterogeneous mice were given chow containing 180 ppm Cana at 7 months of age until their death. Cana extended median survival of male mice by 14%, with p < 0.001 by log-rank test. Cana also increased by 9% the age for 90th percentile survival (p < 0.001 by Wang/Allison test), with parallel effects seen at each of three test sites. Cana did not alter the distribution of inferred cause of death, nor of incidental pathology findings at end-of-life necropsies. No benefits were seen in female mice. The lifespan benefit of Cana is likely to reflect blunting of peak glucose levels, because similar longevity effects are seen in mice given acarbose, a diabetes drug that blocks glucose surges through a distinct mechanism, i.e. slowing breakdown of carbohydrate in the intestine. Interventions that control daily peak glucose levels deserve attention as possible preventive medicines to protect from a wide range of late-life neoplastic and degenerative diseases.